Fivephusion has concluded a drug development partnership deal with Detsamma Investments Pty Ltd. Detsamma will fund the further development of Deflexifol, including completing a bridging trial to gather extra data sought by the FDA.
Detsamma Investments plans to complete the bridging trial in 2020, and follow this with a pre-IND meeting with the FDA.
Detsamma Investments remains open to out-licensing or development partnership discussions to complete the planned pivotal trial for Deflexifol.